OR WAIT null SECS
© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
June 08, 2021
The approval for Biogen’s disease-modifying, anti-amyloid agent aducanumab follows a long regulatory journey.
March 19, 2021
At the 76-week mark, reductions in the amyloid plaque level were 85.06 centiloids with donanemab than with placebo.
February 05, 2021
The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.
December 08, 2020
After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.